Revolution Medicines Inc.
Revolution Medicines Reports Q1 2024 Financial Results and Corporate Update
Summary
Revolution Medicines, Inc. announced its financial results for the quarter ended March 31, 2024, revealing a net loss of $116.0 million, compared to $68.1 million in the prior year. The company reported cash, cash equivalents, and marketable securities of $1.70 billion as of March 31, 2024. The company also provided an update on its clinical development programs, highlighting progress in advancing its RAS(ON) inhibitors into pivotal trials and expanding their use into earlier lines of therapy. Revolution Medicines is reiterating its projected full-year 2024 GAAP net loss to be between $480 million and $520 million.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement